Gewrichten ankylosing spondylitis Bechterew's disease
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Men and women, * 18 and * 70 years of age 2. Diagnosis of ankylosing spondylitis according to the modified New York criteria. 3. The BASDAI score should be * 4. 4. Patients will start with anti-TNF according to clinical care. 5. Treatment with disease modifying anti-rheumatic drugs (DMARDS) and non-steroidal anti-inflammatory drugs (NSAIDs) is permitted, provided that there is a stable dose for at least 2 weeks prior to inclusion and during the study up to 16 weeks of follow up. 6. Patients must be able to adhere to the study appointments and other protocol requirements. 7. Patients must be capable of giving informed consent and the consent must have been obtained prior to the study related procedures.
Exclusion criteria
Exclusion criteria: 1. Treatment with any investigational drug within the previous 3 months. 2. Primary failure of anti-TNF treatment in the past. 3. Pregnancy or breast-feeding. 4. Implanted pacemaker 5. Renal failure with creatinine clearance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. [18F]fluorid uptake in vertebral column and/or SI joints on PET-CT in AS patients with clinically active disease. Sub-study in 2 patients: 2. Quality of the bone biopsy material of PET positive lesions in the vertebral column. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The relation between changes in [18F]-Fluoride PET-CT and clinical monitoring as well as CRP levels during anti-TNF treatment. 2. The relation between [18F]-Fluoride PET-CT outcome as tool for AS monitoring and MRI. | — |
Countries
Netherlands
Outcome results
None listed